Validación de método cromatográfico por HPLC de la valoración e identificación del (1-(1β, 16α)-21-(acetiloxi)-11- hidroxi-2´-metil-5´H-pregna-1,4-dieno[17,16-d]oxazol-3,20- diona) en Deflazacort materia prima

Maya Alejandra Parga; Natalia  Afanasjeva

doi:10.22490/24629448.6920

Vol. 21 No. 40 (2023)

Published 2023-05-01

license

Research Article (before OJS)

Validation of the HPLC chromatographic method for the evaluation and identification of (1-(1β, 16α)-21-(acetyloxy)-11-hydroxy-2´-methyl-5´H-pregna- 1,4-dieno[17, 16-d]oxazole-3,20-diona) in Deflazacort raw material

DOI: https://doi.org/10.22490/24629448.6920

Maya Alejandra Parga Universidad del Valle

Natalia Afanasjeva Universidad del Valle

PDF (Spanish)

Abstract
References

Introduction. Deflazacort (DFZ) is a synthetic ozaxolinic glucocorticoid derived from prednisolone, it has anti-inflammatory properties and acts as an immunosuppressant, is the raw material used as the active ingredient of products marketed in pharmaceutical forms such as tablets and oral suspensions. Objective. Validate the methodology analytical by high performance liquid chromatography (HPLC), for the identification and assessment of (1-(1β,16α)-21-(acetyloxy)-11-hydroxy-2´-methyl-5´H-pregna-1,4 -dieno[17,16-d] oxazol-3,20-diona) in Deflazacort raw material under tropical climate conditions. Methodology.
Using as mobile phase an isocratic mixture of methanol and water in a ratio of 80:20 with a flow of 1, 1mL/min, the column used was Luna® 5μm C8 100Ǻ 250 x 4.6mm, diode array detector at a wavelength of 245nm. Results. For linearity, a correlation coefficient
R ≥ 0.999 was obtained, the coefficient of variation did not exceed the RS D of 2.0% in the repeatability of the system and in intermediate precision between analysts, an RSD value <3.0% was identified, in accuracy a recovery percentage of 98.9% was found.
Conclusions. T he method is l inear, precise, exact, robust for a f low of 1.21mL/min a nd not for a flow of 0.99mL/min since it does not meet retention time. In the performance tests, Deflazacort showed low stability when exposed to degradation by basic hydrolysis with 1.0 N and 0.1 N NaOH solutions. The sample and the standard in solution showed to be stable at room temperature for two hours and refrigerated for three hours.

keywords: high pressure liquid chromatography, immunosuppressive drugs, statistics and numerical data, analytical methods

Huber EW, Barbuch RJ. Spectral analysis and structural identification of a major deflazacort metabolite in man. Xenobiotica. 1995;25(2):175–83.

Markham A, Bryson HM. Deflazacort A Review of its Pharmacological Properties and Therapeutic Efficacy. Drugs. 1995;50(2):317–33.

Özkan Y, Savaşer A, Taş Ç, Uslu B, Özkan SA. Drug dissolution studies and determination of deflazacort in pharmaceutical formulations and human serum samples by RP-HPLC. J Liq Chromatogr Relat Technol. 2003;26(13):2141–56.

Singhai N, Dubey R. Development and Characterization of Deflazacort Nanoparticles for the Treatment of Inflammatory Bowel Disease. People´s J of S.Res. 2021;14(2).

Cuffini SL, Ellena JF, Mascarenhas YP, Ayala AP, Sielser HW, Filho JM, et al. Physicochemical characterization of deflazacort: Thermal analysis, crystallographic and spectroscopic study. Steroids. 2007;72(3):261–9.

Chourasiya Y, Maheshwari R, Tekade RK. Current developments in excipient science: Implication of quantitative selection of each excipient in product development. Basic Fundamentals of Drug Delivery. Elsevier; 2018. p. 29–83.

Scremin A, Piazzon M, Silva MAS, Kuminek G, Correa GM, Paulino N, et al. Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms. Brazilian J Pharm Sci. 2010;46(2):281–7.

Patel M, Jebaliya H, Dabhi B, Jadeja Y, Jani N, Desai D, et al. Chromatography method transfers from HPLC to a new generation instrument UPLC and studies on force degradation behavior of deflazacort. Der Pharm Lett. 2015;7(2):142–9.

Raju CK, Pandey AK, Ghosh K, Pola A, Goud SK, Jaywant MA, et al. Isolation and structural characterization of novel photolytic degradation impurities of Deflazacort using Q-TOF, 2D-NMR and FTIR. J Pharm Biomed Anal. 2017;133:82–9. Available from: http://dx.doi.org/10.1016/j.jpba.2016.11.005

Parente L. Deflazacort: Therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1–8. Available from: http://dx.doi.org/10.1186/s40360-016-0111-8

Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. A Review of Deflazacort for Patients with Duchenne Muscular Dystrophy. Ann Pharmacother. 2020;54(8):788–94.

McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle and Nerve. 2020;61(1):26–35.

López A. E, Ramírez G. G, Iglesias G. A. Instituto Nacional de Vigilancia de Medicamentos y Alimentos: una muerte anunciada. Nova. 2004;2(2):94.

Resolución 00001606 del Ministerio de Salud y Protección Social del 02 de mayo de 2014.

Moreno LB, Romeu CR, Torrez G. Validación del método cromatográfico para estudios de estabilidad del ciprofloxacino clorhidrato 0,2 % gota ótica. Revista Cubana de Farmacia. 2022;55(1):1–14.

Borges LG. Evaluación de los métodos analíticos para el control de calidad de ampicilina y oxacilina. Revista Cubana de Farmacia. 2019;52(1):1–21.

Rodríguez DP, Orta IA, Pérez YS, López GJ. Quality defects during the marketing of pharmaceutical products and the role of regional regulatory authorities. Revista Cubana de Farmacia. 2021;54(3):1–16.

Yapar EA, Özdemirhan ME. An Overview on Pharmacopoeias in the World and Monograph Elaboration Techniques. Univers J Pharm Res. 2020;5(3):57–64.

Guevara M, Mogollón L, Iglesias A, Yupanqui H, Bermúdez A. Estimación de Vitamina D en mujeres con osteopenia y osteoporosis en Cundinamarca-Colombia, por medio de extracción en fase sólida, cromatografía líquida de alta resolución y análisis multivariado. Nova. 2003;1(1):72.

Corrêa GM, Bellé LP, Bajerski L, Borgmann SHM, Cardoso SG. Development and validation of a reversed-phase HPLC method for the determination of deflazacort in pharmaceutical dosage forms. Chromatographia. 2007;65(9–10):591–4.

European Medicines Agency. ICH Topic Q2. Validation of analytical procedures: test and methodology. Encycl Toxicol Third Ed. 1995;2(June 1995):1070–2.

Farmacopea de los Estados Unidos de América (2022). General Chapter, <1225> Validación de procedimientos farmacopeicos. USP-NF. Rockville, MD: Farmacopea de los Estados Unidos de América.

Bor M, Guilarte A, Guzmán L, Mendoza KMW. Validación de un método por RP-HPLC para la determinación de Tiocolchicósido en tabletas. Afinidad. 2018;75(581).

Bermúdez PhD M, Carrillo Bsc Y. Diagnóstico de Homocistinuria y Deficiencia de Adenilosuccinato Liasa a Través de Técnicas Químicas, Bioquímicas y Moleculares. Nova. 2005;3(3):46.

Waters. Empower 3 Software. 2010; 2010. Inc,Thermo Fisher Scientific D. Chromeleon 7, Chromatography data system. 2009.

Chen Y, Xia L, Liang R, Lu Z, Li L, Huo B, et al. Advanced materials for sample preparation in recent decade. TrAC - Trends Anal Chem. 2019;120:115652. Available from: https://doi.org/10.1016/j.trac.2019.115652

Fischer Scientific. Por qué la filtración de muestras y de la fase móvil es esencial para el análisis de HPLC. Thermo Fischer Scientific. 2022. Tomo 22.036. Folio 17. Inscripción 1a, C.I.F. B-84498955

Farmacopea de los Estados Unidos de América (2022). General Chapter, <621> Cromatografía.USP-NF. Rockville, MD: Farmacopea de los Estados Unidos de América.

Farias FF, Martins VAP, Yano HM, Trujillo LM, Pinto E. Forced degradation studies to identify organic impurities in pharmaceuticals: A brazilian perspective. Rev Ciencias Farm Básica e Apl. 2021;42:1–13.

Thorat SS, Gupta A. Basic Concept of Stability Profile and Stress Degradation Pathway of Pharmaceutical Formulations: A Review. J Biol Chem Chron. 2018;4(3):34–42.

Bhaskar R, Ola M, Agnihotri V, Chavan A, Girase H. Current Trend in Performance of Forced Degradation Studies for Drug Substance and Drug Product’s. J Drug Deliv Ther. 2020;10(2-s):149–55.

Verbić T, Dorkó Z, Horvai G. Selectivity in analytical chemistry. Rev Roum Chim. 2013;58(7–8):569–75.

Avila J. Validación del método analítico de contenido e identificación de prednisolona sodio fosfato (base) en prednisolona 5mg/ml solución oral. [Internet]. Universidad Nacional de Trujillo; 2012. Available from: https://dspace.unitru.edu.pe/bitstream/handle/UNITRU/10406/AmayaHilarioCarmenVictoria.pdf?sequence=1&isAllowed=y

Divyashree S, Veena MK, Channabasavaraj KP. Method Validation for Simultaneous Estimation of Prednisolone and Abiraterone Acetate by RP-HPLC. J Chronother Drug Deliv. 2016;7:41–9.

Díaz EM, San Cristóbal M, Alarcón B, Córdoba C, Legaz M. Curso de cromatografía de líquidos de alta resolución (HPLC): Prácticas de laboratorio y cuestiones teórico-prácticas. Parte II. Práctica de laboratorio: análisis cuantitativo básico. Reduca (Biología). 2011;4(3):33–47.

Sierra N, Gómez G. Desarrollo y validación de una metodología por cromatografía líquida de alta eficiencia para la determinación simultánea de piperacilina sódica y tazobactam sódico en inyectables para uso humano. Rev Colomb Ciencias Químico-Farmacéuticas. 2014;43(1):5–21.

Kruve A, Rebane R, Kipper K, Oldekop ML, Evard H, Herodes K, et al. Tutorial review on validation of liquid chromatography-mass spectrometry methods: Part II [Internet]. Vol. 870, Analytica Chimica Acta. Elsevier B.V.; 2015. 8–28 p. Available from: http://dx.doi.org/10.1016/j.aca.2015.02.016

Ruiz DJ, Afanasjeva N. Método de cuantificación enzimática con DNS para ß-mananasa en soya y en un aditivo nutricional. Cienc y Agric. 2022;19(3):57–72.

European Medicines Agency. ICH Q1A (R2). Stability testing of new drug substances and drug products. 2003.

Cámara MS., Guerrero F., Alasino A., Caro Y., De Zan MM. Desarrollo y validación de un método analítico indicativo de estabilidad por CLAR para la evaluación de la pureza cromatográfica y la cuantificación simultánea de ibuprofeno y su compuesto relacionado 4-isobutilacetofenona en materias primas. Rev Mex Ciencias Farm. 2017;48(4°):59. Available from: http://www.redalyc.org/articulo.oa?id=57956617007

Waters. How do you set up the Purity Thresholds in Empower 3? [Internet]. Waters knowledge base. 2021. Available from: https://support.waters.com/KB_Inf/Empower_Breeze/WKB11215_How_do_you_set_up_the_Purity_Thresholds_in_Empower_3

Llinas S H. Regresión Lineal simple: Pruebas de hipótesis. Estadística básica y avanzada. Rpubs. Ed. Universidad del Norte, 2021.

license

How to Cite

Parga, M. A., & Afanasjeva, N. (2023). Validation of the HPLC chromatographic method for the evaluation and identification of (1-(1β, 16α)-21-(acetyloxy)-11-hydroxy-2´-methyl-5´H-pregna- 1,4-dieno[17, 16-d]oxazole-3,20-diona) in Deflazacort raw material. NOVA Biomedical Sciences Journal, 21(40), 119-139. https://doi.org/10.22490/24629448.6920

Download Citation

Almétricas

Captures

Readers: 2

see details

Metrics

Archivos descargados

648

Declaración de privacidad.

Validation of the HPLC chromatographic method for the evaluation and identification of (1-(1β, 16α)-21-(acetyloxy)-11-hydroxy-2´-methyl-5´H-pregna- 1,4-dieno[17, 16-d]oxazole-3,20-diona) in Deflazacort raw material

Declaración de privacidad.